Studies on the anticlastogenic effect of turmeric and curcumin on cyclophosphamide and mitomycin C in vivo.
Turmeric and its main constituent curcumin were assessed in vivo for their anticlastogenic potential. In one experimental set, Swiss albino male mice were given turmeric (8, 12 and 16 mg/kg body weight) or curcumin (2, 4 and 8 mg/kg body weight) as a single intraperitoneal injection. In another set, the mice were given 8 mg/kg body weight of turmeric or one of three concentrations of curcumin (2, 4 and 8 mg/kg body weight) as a dietary supplement by gavage for 7 consecutive days. 30 min after the last dose the mice were administered a single acute dose of two known clastogens, cyclophosphamide (CP) (20 mg/kg body weight) or mitomycin C (MMC) (1.5 mg/kg body weight). After 18 hr, chromosome preparations were made from bone marrow cells. The endpoints studied were chromosome aberrations and damaged cells. Clastogenicity of the chemicals was compared using turmeric- or curcumin-primed and non-primed animals. As single agents turmeric and curcumin were not clastogenic even after 7 days of priming. Turmeric/curcumin could not inhibit CP- or MMC-induced clastogenicity. Although curcumin is reported to be the active chemopreventive principle in turmeric effective against a number of potential carcinogens in several experimental systems, it was virtually ineffective against the clastogenicity of CP or MMC at the doses tested.
Mukhopadhyay
M J
MJ
Department of Botany, University of Calcutta, India.
Saha
A
A
Mukherjee
A
A
D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology*; D002869:Chromosome Aberrations; D003474:Curcumin / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000037:antagonists & inhibitors* / Q000633:toxicity; D008297:Male; D051379:Mice; D016685:Mitomycin / Q000037:antagonists & inhibitors* / Q000633:toxicity; D009153:Mutagens / Q000494:pharmacology
D016587:Antimutagenic Agents; D009153:Mutagens; D016685:Mitomycin; D003520:Cyclophosphamide; D003474:Curcumin